CytoDyn (OTCMKTS:CYDY) Shares Up 19.1% – Still a Buy?

CytoDyn Inc. (OTCMKTS:CYDY) traded up 19.1% during mid-day trading on Friday . The stock traded as high as $0.40 and last traded at $0.40. Approximately 4,722,506 shares changed hands during mid-day trading, an increase of 37% from the average session volume of 3,440,868 shares. The stock had previously closed at $0.34.

CytoDyn Stock Performance

The business has a 50-day simple moving average of $0.25 and a 200 day simple moving average of $0.19. The firm has a market cap of $497.26 million, a P/E ratio of -39.90 and a beta of 1.15.

About CytoDyn

CytoDyn Inc, a clinical-stage biotechnology company, engages in the development of treatments for multiple therapeutic indications. The company is involved in the clinical development of leronlimab, a novel humanized monoclonal antibody targeting the C-C chemokine receptor type 5 receptor in the areas of COVID-19, human immunodeficiency virus (HIV), Metabolic dysfunction-associated steatohepatitis (MASH), and solid tumors in oncology, such as metastatic triple-negative breast cancer.